
    
      To evaluate the progression free survival of patients with extensive stage small cell lung
      cancer treated with anlotinib combined with EP/CE regimen To evaluate the safety,
      tolerability, overall survival (OS), objective response rate (ORR), disease control rate
      (DCR), and quality of life (QoL) of patients with extensive stage small cell lung cancer
      treated with anlotinib
    
  